Experience
18 Minute
Parts 1 and 2 of this series examined how disease can rise alongside medical advancement, and how regulatory failure allowed persistent chemicals such as PFAS to become embedded across Australia. The final question is the most important one.
If the problem is systemic, what does prevention actually look like?
From a systems perspective, prevention is not a public health slogan. It is a design problem. And Australia’s experience with PFAS provides a clear lens through which to understand how future harm could be reduced rather than endlessly managed.
As Craig Astill has repeatedly emphasised, systems do not drift into failure by accident. They fail when incentives, oversight and long-term biological realities are misaligned.
PFAS did not slip through the cracks. They moved straight through a system that rewarded durability, scale and performance while discounting persistence, accumulation and delayed harm.
One of the clearest Australian examples is the long-running PFAS contamination around RAAF Base Williamtown in New South Wales. Firefighting foams were used for decades before contamination of soil and groundwater was acknowledged. By the time residents were informed, PFAS had already entered water systems, local food chains and human blood samples.
Medical monitoring programs were eventually introduced. Compensation schemes followed. Water infrastructure was upgraded. But all of these responses occurred after exposure had become unavoidable.
A similar pattern emerged near RAAF Base Tindal in the Northern Territory and Oakey Army Aviation Centre in Queensland. In each case, the response focused on containment, health surveillance and remediation, rather than questioning why chemicals with no biological exit pathway were approved for widespread use in the first place.
These are not failures of medicine or emergency response. They are examples of downstream mitigation substituting for upstream prevention.
International comparisons reinforce the same lesson.
In the United States, PFAS contamination around military bases and manufacturing hubs followed an almost identical trajectory. The difference is scale. With a larger industrial footprint, exposure was broader and litigation more aggressive. Regulation still lagged production by decades.
In contrast, parts of Scandinavia provide a useful counterexample. Countries such as Sweden and Denmark moved earlier to restrict PFAS in consumer products once persistence data became clear. While exposure still occurred, the window of accumulation was shorter, and replacement materials were prioritised sooner.
The European Union’s recent move toward a group-wide PFAS restriction, rather than regulating individual compounds one by one, reflects a systems correction. Instead of chasing chemistry after damage is done, the EU is beginning to treat persistence itself as disqualifying.
Australia has historically followed rather than led in this space. That does not reflect a lack of scientific capability. It reflects institutional design choices.
Prevention struggles when responsibility is fragmented.
Chemical approval systems assess acute toxicity. Environmental regulators assess contamination after detection. Health systems respond once symptoms appear. Each institution performs its function competently, yet no single system owns the full lifecycle risk.
As Craig Astill has articulated in broader infrastructure and capital discussions, when accountability is distributed without integration, risk accumulates invisibly until it crosses a threshold.
PFAS crossed that threshold quietly.
True prevention requires shifting focus away from individual chemicals and toward system properties.
Three redesign principles emerge clearly from Australia’s experience.
First, persistence must be treated as a primary risk factor. Any compound designed to resist breakdown should face a higher regulatory burden before widespread adoption. Durability in materials should trigger caution, not convenience.
Second, lifecycle accountability must be embedded into production incentives. Manufacturers and large-scale users should remain responsible not just for performance during use, but for environmental and biological impact long after disposal. When long-term costs are internalised, material choices change quickly.
Third, health systems must be connected to production systems earlier. Surveillance data, environmental monitoring and biomonitoring should feed directly into regulatory thresholds, not remain siloed as academic or advisory signals.
These shifts do not require abandoning innovation. They require aligning innovation with biological reality.
Australia’s response to PFAS has cost billions in remediation, water treatment upgrades, legal settlements and ongoing health monitoring. None of those investments remove PFAS already circulating in ecosystems.
By contrast, early restriction would have reduced exposure permanently at a fraction of the cost.
This is the paradox of prevention. It appears expensive when risk is abstract, but trivial when compared to downstream burden.
As Craig Astill has observed in long-cycle system analysis, the most expensive outcomes are usually the ones no system was designed to see coming.
Australia’s PFAS story is not unique. It is a preview.
Future health challenges will increasingly emerge from material science, environmental load and system-level exposure rather than infectious disease alone. Medicine will continue to advance. Disease prevalence will continue to reflect how upstream systems are designed.
Prevention, in this context, is not about individual behaviour. It is about whether societies are willing to redesign production, regulation and accountability before biological limits are exceeded.
Parts 1 and 2 showed how disease rises alongside progress and how regulation failed to keep pace with production.
Part 3 makes the conclusion unavoidable.
If systems are not redesigned upstream, health will always be managed downstream.
The choice is not between innovation and safety.
It is between designed prevention and permanent remediation.
Have a question or opportunity to discuss?
Reach out anytime at enquiries@craigastill.com.au
© 2028. Craigastill.com.au All rights reserved.
